Is Jubilant Ingrev. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Jubilant Ingrev. has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 36.66, an EV to EBITDA of 19.92, and a PEG ratio of 0.57, which suggests that while growth expectations are present, the current price may not justify the earnings potential.
In comparison to its peers, Jubilant Ingrev. has a higher PE ratio than Sun Pharma. Inds. at 35.17 and significantly outstrips Cipla, which has a PE of 22.33, highlighting its relative overvaluation. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.49% compared to the Sensex's 6.50%, further reinforcing the notion that the stock may be overpriced in the current market environment.